News & Events

IMS Studies Utilize CoMMpass Genomic Data in Multiple Myeloma Research

The data created by the CoMMpass longitudinal genomic profiling study (NCT01454297) was employed in several significant clinical trials presented at the 19th International Myeloma Society (IMS) annual meeting, according to a press release from the Multiple Myeloma Research Foundation (MMRF).

The CoMMpass, or Clinical Outcomes in Multiple Myeloma Personal Assessment of Genetic Profiles trial, which collected data from an estimated 1150 patients worldwide, provided data that were cited in 19 abstracts at IMS, including 4 oral presentations. It was also announced that the Multiple Myeloma Research Consortium presented results from the MyDRUG clinical trial (NCT03732703) that investigated targeted therapies with precision medicine in patients with multiple myeloma.

*Read the full article at Targeted Oncology*